This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
HOOKIPA (HOOK), Merck Collaborate to Treat Head & Neck Cancers
by Zacks Equity Research
HOOKIPA (HOOK) collaborates with Merck (MRK) to evaluate the combination of its immunotherapy program, HB-200, with Merck's Keytruda for advanced head and neck squamous cell carcinoma.
Theravance (TBPH) to Cut Workforce, Hypotension Study Fails
by Zacks Equity Research
Theravance's (TBPH) phase III study on ampreloxetine for treating symptomatic neurogenic orthostatic hypotension fails to meet goal. The company plans to cut its workforce by 75%. Stocks falls.
AstraZeneca (AZN) Asthma Candidate Meets Primary Study Goals
by Zacks Equity Research
AstraZeneca's (AZN) phase III studies evaluating its investigational inhaler PT027 for asthma meets primary endpoints.
Adaptimmune (ADAP) Gains on Deal With Roche for Cell Therapies
by Zacks Equity Research
Adaptimmune (ADAP) shares jump on a collaboration and license agreement with Roche for the development of allogeneic T-cell therapies for up to five shared cancer targets.
Merck's (MRK) Keytruda Gets Nod for Expanded Use in China
by Zacks Equity Research
Merck's (MRK) Keytruda gets approval in combination with chemotherapy in the first-line setting for advanced esophageal and GEJ cancer in China based on data from the phase III KEYNOTE-590 study.
Will Regeneron's (REGN) Antibody Cocktail Fuel Further Growth?
by Zacks Equity Research
Regeneron's (REGN) performance in the year has gained from higher demand for its antibody cocktail - REGEN-COV.
Adaptimmune (ADAP) Presents Data on Liver Cancer Candidate
by Zacks Equity Research
Adaptimmune (ADAP) announces encouraging data from an early-stage study on liver cancer patients from its cell therapy candidate.
Pfizer (PFE) Begins Study on RSV Vaccine in Older Adults
by Zacks Equity Research
Pfizer (PFE) starts a phase III study which will evaluate its respiratory syncytial virus vaccine candidate, RSVpreF in adults aged 60 years and above.
GlaxoSmithKline (GSK) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
GlaxoSmithKline (GSK) closed at $41.43 in the latest trading session, marking a +0.78% move from the prior day.
Glaxo (GSK), SK bioscience's COVID-19 Jab Enters Phase III Study
by Zacks Equity Research
GlaxoSmithKline (GSK) and SK bioscience begin a phase III study on GBP510, the latter's COVID-19 vaccine candidate. The study will compare GBP510 against AstraZeneca's COVID-19 vaccine.
J&J's (JNJ) HIV Vaccine Study in Young African Women Fails
by Zacks Equity Research
J&J's (JNJ) mid-stage study shows HIV vaccine fails to provide enough protection against HIV in young women in Africa.
Merck's (MRK) Keytruda Gets Full Approval for Bladder Cancer
by Zacks Equity Research
Merck's (MRK) anti-PD-1 therapy, Keytruda, gets full approval from the FDA as a first-line treatment for bladder cancer, after having enjoyed accelerated approval for the indication.
3 Big Drug/Biotech Outperformers Worth Keeping an Eye On (Revised)
by Kinjel Shah
Eli Lilly (LLY), Pfizer (PFE) and Novo Nordisk (NVO) are three large drugmakers that have outperformed the industry and are good stocks to hold for the next few months and beyond.
Theravance (TBPH) Suffers 2nd Study Failure in Two Months
by Zacks Equity Research
Theravance's (TBPH) mid-stage candidate, izencitinib, fails in a study evaluating it in patients with ulcerative colitis.
Regeneron (REGN) COVID-19 Antibody Cocktail Gets CMA in the UK
by Zacks Equity Research
Regeneron (REGN) gets Conditional Marketing Authorization for its antibody cocktail, casirivimab and imdevimab for COVID-19 infection in the United Kingdom.
Gilead (GILD) MAA for HIV Inhibitor Under the EMA's Review
by Zacks Equity Research
Gilead's (GILD) application for an investigational, long-acting HIV-1 capsid inhibitor, lenacapavir, is under review with the European regulatory body.
Pharma Stock Roundup: FDA Nod for MRK, PFE Products & New Use of LLY, GSK Drugs
by Kinjel Shah
FDA approves Merck's (MRK) Welireg and Pfizer's (PFE) TICOVAC vaccine and new indications for Lilly's (LLY) Jardiance and Glaxo's (GSK) Jemperli.
Top Analyst Reports for Chevron, T-Mobile & American Express
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including Chevron Corporation (CVX), T-Mobile US, Inc. (TMUS), and American Express Company (AXP).
Regeneron (REGN) Antibody Cocktail for COVID-19 Gets a Boost
by Zacks Equity Research
Regeneron (REGN) antibody cocktail for COVID-19 receives a boost as the Governor of Florida recommends it for COVID-19 treatment.
Biotech Stock Roundup: MRNA Vaccine Updates, Other Regulatory News & Collaborations
by Zacks Equity Research
Regulatory and pipeline updates from Moderna (MRNA) and CureVac (CVAC) among others were in focus in the biotech industry over the past week.
Glaxo's (GSK) Jemperli Gets FDA Approval for New Indication
by Zacks Equity Research
The FDA grants accelerated approval to Glaxo's (GSK) Jemperli for treating patients with mismatch repair-deficient recurrent/advanced solid tumors. This is the second approved indication for the drug.
3 Big Drug/Biotech Outperformers Worth Keeping an Eye On
by Kinjel Shah
Eli Lilly (LLY), Pfizer (PFE) and Novo Nordisk (NVO) are three large drugmakers that have outperformed the industry and are good stocks to hold for the next few months and beyond.
Merck's (MRK) VHL-Linked Tumor Drug Welireg Gets FDA Nod
by Zacks Equity Research
Merck's (MRK) Welireg (belzutifan) is the first and only systemic therapy approved for treating patients with certain types of von Hippel-Lindau (VHL) disease-associated tumors.
Rigel (RIGL) COVID-19 Treatment Denied By FDA for EUA
by Zacks Equity Research
Rigel Pharmaceuticals' (RIGL) fostamatinib does not get the FDA's nod for emergency use for COVID-19. The company plans to submit data from a larger study.
Merck's (MRK) Keytruda/Lenvima Get FDA Nod for Kidney Cancer
by Zacks Equity Research
FDA approves Merck's (MRK) Keytruda + partenr Eisai's Lenvima for advanced RCC in the first-line setting based on data from the phase III CLEAR/KEYNOTE-581 study.